Taysha Gene Therapies, Inc. (TSHA)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Adeno-Associated Viruses-based Gene Therapies	15.45M	Log In
Adeno-Associated Viruses-based Gene Therapies Growth	517.55%	Log In

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	15.45M	Log In
United States Growth	517.55%	Log In